loader

C4 Therapeutics Inc.

NASDAQ:CCCC
1 min read

Precision Oncology Approaches Drive $312B Market Transformation

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society Annual Meeting

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES